Robert Herman Vonderheide, MD, DPhil
Penn Medicine Provider
About me
- Director of the Abramson Cancer Center
- John H. Glick Abramson Cancer Center Professor
Dr. Vonderheide is an internationally renowned cancer immunotherapy and translational research expert. Through a focus on novel immunotherapies for pancreatic cancer, melanoma and breast cancers, Dr. Vonderheide has mapped new models for speeding translational - or "bench to bedside" research. He is currently the Director of the Abramson Cancer Center.
My education and training
- Harvard UniversityMedical School
- Massachusetts General HospitalResidency
- Dana-Farber Cancer InstituteFellowship
Spoken languages
English
English
Insurance accepted
Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Americhealth Caritas of PA VIP - LGH Only
- Amerihealth Caritas (Transplant patients only)
- Amerihealth Caritas of PA - LGH Only
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
- Clover Health Choice
- Clover Health Choice Value PPO
- Clover Health Classic HMO
- Clover Health Value
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Vonderheide is a Penn Medicine physician.
Qualifications and experience
- Medical Oncology, 2000
- American Association of Cancer Research Cancer Immunology Working Group, National
- American Association of Cancer Research, National
- American Association of Physicians, National
- American Society of Clinical Investigation, National
- American Society of Clinical Oncology, National
- Cancer Immunotherapy Trials Network, National Cancer Institute, National
- Cancer Research Institute, National
- Case Western Comprehensive Cancer Center, National
- Chicago Comprehensive Cancer Center, National
- Dartmouth Norris Cotton Cancer Center, National
- National Cancer Institute, Board of Scientific Advisors, National
- National Institutes of Health, Cancer Immunopathology and Immunotherapy Study Section, National
- New York University Langone Medical Center, Perlmutter Cancer Center, National
- University of North Carolina Lineberger Comprehensive Cancer Center, National
- University of Pittsburgh Cancer Institute, National
- Yale Cancer Center, National
Treatments and conditions
Research
Publications
Bear AS, Blanchard T, Cesare J, Ford MJ, Richman LP, Xu C, Baroja ML, McCuaig S, Costeas C, Gabunia K, Scholler J, Posey AD Jr, O'Hara MH, Smole A, Powell DJ Jr, Garcia BA, Vonderheide RH*, Linette GP*, Carreno BM*. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. , Nat Commun., 12: 2021
Macedo R, Pasin C, Ganetsky A, Harle D, Wang XK, Belay K, Richman LP, Huffman AP, Vonderheide RH, Yates AJ, Porter DL, Wang Y, Zhang Y, Reshef R. Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature. . , S2666-6367(21)01260-4: 2021
Vonderheide RH, Kraynyak KA, Shields AF, McRee AJ, Johnson JM, Sun W, Chintakuntlawar AV, Pawlicki J, Sylvester AJ, McMullan T, Samuels R, Kim JJ, Weiner D, Boyer JD, Morrow MP, Humeau L, Skolnik JM. Phase 1 study of safety, tolerability, and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO01401 with or without IL-12 DNA plasmid IND-9012 in adult patients with solid tumors. , J Immunother Cancer: 2021
Diamond MS, Lin JH, Vonderheide, RH. Site-dependent immune escape of highly antigenic tumors without immunoediting. , Cancer Immunol Res., 9: 2021,877-890
Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Liudahl SM, Betts CB, Sivagnanam S, Morales-Oyarvide V, DaSilva A, Yua.n C, Hwang S, Grossblatt-Wait A, Leis KR, Larson W, Lavoie MB, Robinson P, Costa Ad, Vayrynen SA, Clancy TE, Robinson DA, Link J, Keith D, Horton W, Tempero MA, Vonderheide RH, Jaffee EM, Sheppard B, Goecks J, Sears RC, Park BS, Mori M, Nowak JA, Wolpin BM, Coussens LM. , Cancer Discovery, 11: 2021,2014-2031
Reiss KA, Mick R, O’Hara MH, Teitelbaum U, Karasic TB, Schneider C, Cowden S, Southwell T, Romeo J, Izqur N, Hannan ZM, Tondon R, Nathanson K, Vonderheide RH, Wattenberg MM, Beatty G, Domchek SM. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. , J Clin Oncol, 39: 2021,2497-2505
Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Hwee MA, Porterfield Fl, Owoyemi O, Naik K, Zheng C Galantino M, Weisman AR, Ittner CAG, Kugler EM, Baxter AE, Oniyide O, Agyekum, RS, Dunn TG, Jones TK, Giannini HM, Weirick ME, McAllister CM, Babady NE, Kumar A, Widman AJ, DeWolf S, Boutemine SR, Roberts C, Budzik KR, Tollet S, Wright C, Perloff T, Sun L, Mathew D, Giles JR, Oldridge DA, Wu JE, Alanio C, Adamski S, Garfall AL, Vella LA, Kerr SJ, Cohen JV, Oyer RA, Massa R, Maillard IP, Maxwell KN, Reilly JP, Maslak PG, Vonderheide RH, Wolchok JD, Hensley SE, Wherry EJ, Meyer NJ, DeMichele AM, Vardhana SA, Mamtani R, Huang AC. CD8 + T cells contribute to survival in patients with COVID-19 and hematologic cancer. , Nat Med., 27: 2021,1280-1289
Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O’Hara MH, Liudahl SM, Newcomb CW, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman A, Vayrynen SA, Costa AD, Kaiser JC, Lacroix AM, Redlinger C, Stern M, Nowak JA, Wherry EJ, Cheever MA, Wolpin BM, Furth EE, Jaffee EM, Coussens LM, Vonderheide RH. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. , Clin. Cancer Res., 27: 2021,4574-4586
Sun L, Surya S, Goodman NG, Le AN, Kelly G, Olutosin O, Desai H, Zheng C, DeLuca S, Good ML, Hussain J, Jeffries SD, Kry YR, Kugler EM, Mansour M, Ndicu J, Osei-Akoto A, Prior T, Pundock SL, Varughese LA, Weaver J, Doucette A, Dudek S, Verma SS, Gouma S, Weirick MD, McAllister CM, Bange E, Gabriel P, Ritchie M, Rader DJ, Vonderheide RH, Schuchter LM, Verma A, Maillard I, Mamtani R, Hensley SE, Gross R, Wileyto EP, Huang AC, Maxwell KN, DeMichele A. SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. , JCO Oncol Pract.: 2021
Yang F, He Z, Duan H, Zhang D, Li J, Yang H, Dorsey JF, Zou W, Nabavizadeh SA, Bagley SJ, Abdullah K, Brem S, Zhang L, Xu X, Byrne KT, Vonderheide RH, Gong Y, Fan Y. Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. , Nat Commun., 12: 2021